Abstract
Restless legs syndrome is an underdiagnosed sensori-motor disorder and psychotropic drugs are one of the main secondary causes of the illness. The most common psychotropic agents that cause restless legs syndrome are antidepressants; however, antipsychotics have also been reported to induce restless legs syndrome. The prevalence, vulnerability factors and the underlying mechanism of antipsychotic-induced restless legs syndrome are unclear. A possible explanation is that dopaminergic blockade is the main precipitator of the syndrome. Quetiapine-induced restless legs syndrome is another point of interest because of its low binding to D2 receptors. We herein report the case of a restless legs syndrome that emerged after a single low dose quetiapine administration.
Keywords: Restless legs syndrome, clozapine, psychotropic drugs, quetiapine, risperidone.
Current Drug Safety
Title:Restless Legs Syndrome After Single Low Dose Quetiapine Administration
Volume: 11 Issue: 2
Author(s): Ahmet Z. Soyata, Fahri Celebi and Lutfi I. Yargc
Affiliation:
Keywords: Restless legs syndrome, clozapine, psychotropic drugs, quetiapine, risperidone.
Abstract: Restless legs syndrome is an underdiagnosed sensori-motor disorder and psychotropic drugs are one of the main secondary causes of the illness. The most common psychotropic agents that cause restless legs syndrome are antidepressants; however, antipsychotics have also been reported to induce restless legs syndrome. The prevalence, vulnerability factors and the underlying mechanism of antipsychotic-induced restless legs syndrome are unclear. A possible explanation is that dopaminergic blockade is the main precipitator of the syndrome. Quetiapine-induced restless legs syndrome is another point of interest because of its low binding to D2 receptors. We herein report the case of a restless legs syndrome that emerged after a single low dose quetiapine administration.
Export Options
About this article
Cite this article as:
Z. Soyata Ahmet, Celebi Fahri and I. Yargc Lutfi, Restless Legs Syndrome After Single Low Dose Quetiapine Administration, Current Drug Safety 2016; 11 (2) . https://dx.doi.org/10.2174/1574886311207040298
DOI https://dx.doi.org/10.2174/1574886311207040298 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Current Alzheimer Research Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Meet Our Associate Editor
Current Alzheimer Research Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Functional Neurochemistry of Alzheimers Disease
Current Pharmaceutical Design Industrial Production of the Cell Protectant Ectoine: Protection Mechanisms, Processes, and Products
Current Biotechnology An Overview of Olive Oil Biomolecules
Current Biotechnology Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Prevention and Treatment of Allergic Asthma in Pregnancy: From Conventional Drugs to New Therapeutical Approaches
Current Pharmaceutical Biotechnology Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
Mini-Reviews in Medicinal Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Painful Peripheral Neuropathies
Current Neuropharmacology Suicide and Suicide Attempts in Elderly Patients: An Epidemiological Analysis of Risk Factors and Prevention
Current Pharmaceutical Design γ-Secretase Inhibition and Modulation for Alzheimers Disease
Current Alzheimer Research The Effect of a Spiritual Care on Hope in Patients Undergoing Hemodialysis: A Randomized Controlled Trial
Current Psychiatry Research and Reviews Age-Associated Changes in Immune Function: Impact of Vitamin E Intervention and the Underlying Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug
Current Chemical Biology Obstructive Sleep Apnea and Obesity
Current Respiratory Medicine Reviews